GEN-MKT-18-7897-A
Jun 9, 2022 | Agriculture, Blogs, Environmental / Industrial, Industrial, Other | 0 comments
Read Time: 3 minutes
Per-and polyfluorinated alkyl substances (PFAS) are known for their water- and grease-resistant properties, which make them useful in many everyday items. In fact, a study from 2020 estimated over 200 “use categories” covering more than 1,400 individual PFAS compounds in commercial products1—they are truly all around us. Due to their extensive presence and potentially harmful effects (these effects are still mostly uncertain), exposure to PFAS is a growing concern. Humans and wildlife have been exposed to these chemicals through a variety of routes, including food packaging, drinking water and cleaning products.2
The potential health risks of PFAS chemicals stem from a combination of “exposure” and inherent “toxicity,” so it is essential to properly identify and quantify PFAS exposure. So, how do we monitor exposure to contaminants such as PFAS?
Monitoring human exposure to contaminants
When individuals are exposed to PFAS, the PFAS accumulate in protein-rich tissues such as blood, liver and kidneys. For this reason, biological examination of PFAS exposure is often conducted using blood matrices. However, many of the approaches used for this type of examination are difficult to conduct when looking at exposures across a population.3 For example, obtaining a statistically significant sample size in a moderately sized city or country requires a lot of human samples. These large studies can be difficult to coordinate, not to mention the difficulties involved with handling human samples.
Another option is using environmental matrices to monitor exposure. Wastewater, for instance, can serve as a powerful tool for assessing the chemical use or consumption patterns of a population over time.4 For many years, wastewater has been used to monitor contaminants such as personal care products and pharmaceuticals (PPCPs) and illegal drugs, and it can also play an important role with PFAS.
Understanding the fate of PFAS through water treatment plants (WTPs) and wastewater treatment plants (WWTPs) can benefit society in addressing PFAS issues.5 While WTPs and WWTPs can remove some contaminants, these plants are not designed to break down persistent organic pollutants such as PFAS, which means that they are detected in the final effluent. This, of course, has implications for aquatic toxicity in the receiving sources, but it can also inform us about PFAS exposure trends within the community.
Analyzing PFAS trends using wastewater
In a recent study from the Queensland Alliance for Environmental Health Sciences and its collaborators, scientists accessed a 10-year wastewater archiving program to conduct a temporal analysis of PFAS trends in an urban Australian population between the years 2010 and 2020. Although the results showed a decline in concentrations for most PFAS, the study also observed a shift in the types of PFAS compounds detected. Specifically, the researchers measured greater proportions of shorter chain-length PFAS as well as replacement compounds.4 These results imply significant shifts in community exposure to PFAS—both the magnitude of exposure and the specific compounds that people were exposed to—which has an impact on the potential human health risk.
Observing these historical trends would have been extremely difficult using traditional exposure techniques such as measuring PFAS serum levels. This study is a useful example of how creative approaches and mass spectrometry can improve our understanding of the human health risk of PFAS.
References
RUO-MKT-18-14771-A
The Echo® MS+ system is a novel platform for Acoustic Ejection Mass Spectrometry (AEMS) and combines the speed of acoustic sampling with the selectivity of mass spectrometry. This platform has been designed for high throughput analysis of small and large molecules. The technology combines Acoustic Droplet Ejection (ADE), an Open Port Interface (OPI) and could be coupled with the SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system.
The Echo® MS+ system comprises of an open-port interface (OPI) and acoustic droplet ejection (ADE) module which could be coupled with a mass spectrometer. The mass spectrometer could either be a SCIEX Triple Quad 6500+ system or the ZenoTOF 7600 system. This non-liquid chromatography based; high-throughput screening platform enables rapid analysis of compounds at speeds of up to 1 sample/second.
The ability to consistently achieve reproducible results on many complex samples across multiple days is critical to a routine clinical laboratory. Laboratories relying on analytical instrumentation require stability and robustness to perform a variety of screening and confirmatory assays with confidence. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the preferred analytical method in the clinical laboratory to reliably perform clinical testing as it provides best-in-class performance and reliability for the most challenging assays. LC-MS/MS offers the required levels of sensitivity and specificity for the detection and quantitation of molecules from complex biological samples, helping laboratories deliver highly accurate data for a variety of clinically relevant analytes across a wide range of assays.
Posted by
You must be logged in to post a comment.
Share this post with your network